Evaluation of Changes Over Time in the Drug Burden and Medication Regimen Complexity in ESRD Patients Before and After Renal Transplantation - ScienceDirect
Cancers | Free Full-Text | Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review | Journal of the American Heart Association
![PDF] Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite” | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9ac5e5e50d735ecf3baed58f3854dd1fa050a509/4-Figure1-1.png "PDF] Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite” | Semantic Scholar")
PDF] Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite” | Semantic Scholar
Frontiers | The immunosuppressive microenvironment and immunotherapy in human glioblastoma
Patient-centred approaches for the management of unpleasant symptoms in kidney disease | Nature Reviews Nephrology
Frontiers | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets | Journal of Hematology & Oncology | Full Text
Targeting immunosuppressive adenosine in cancer | Nature Reviews Cancer
Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNFα and IL-12 gene electrotransfer - ScienceDirect
Cancer Risk Among Immunosuppressed Populations - NCI
Zoledronic Acid–Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment | ACS Nano
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance | npj Precision Oncology
Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? - ScienceDirect
Clinical use of dendritic cells for cancer therapy - The Lancet Oncology
H.R. 5534 Passed: Lifetime Medicare Coverage of Immunosuppressant for Kidney Recipients - American Transplant Foundation
Correlating total mutational burden with response to PD-1/L1 blockade... | Download Scientific Diagram
Frontiers | Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients
Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making - Hellemans - 2021 - Transplant International -
Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy | Journal for ImmunoTherapy of Cancer
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy - ScienceDirect
Clinical challenges in cancer patients with COVID-19: Aging, immunosuppression, and comorbidities | Aging
Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer - eBioMedicine
Transplantology | Free Full-Text | Strategies to Improve Immune Suppression Post-Liver Transplantation: A Review
Frontiers | Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment | Cellular & Molecular Immunology
Systemic immunity in cancer | Nature Reviews Cancer
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study | Request PDF
